规格

价格

库存

数量

1 mg

¥ 1,370

现货

5 mg

¥ 3,450

现货

10 mg

¥ 4,910

现货

25 mg

¥ 7,850

现货

50 mg

¥ 10,500

现货

100 mg

¥ 14,270

现货

生物活性

产品描述	Paricalcitol is a selective vitamin D receptor agonist and a vitamin D analog. Paricalcitol potently inhibits the synthesis and secretion of parathyroid hormone (PTH) and is commonly used in studies of secondary hyperparathyroidism in patients with chronic kidney disease.
体外活性	方法：人脐静脉内皮细胞（HUVEC）使用不同浓度 Paricalcitol（50-500 nM）预处理细胞 24 小时，然后更换培养基并加入 100 µM H₂O₂处理 3 小时，使用 MTT 法检测细胞活力。结果：在 500 nM 浓度下，Paricalcitol 在损伤后处理能显著提高细胞活力。[1]
体内活性	方法：为验证 Paricalcitol 在 CPPD 诱导的急性肾损伤(AKI)中的作用，将 Paricalcitol (0.3 μg/kg) 单剂量腹腔注射给 C57BL/6 小鼠，3 d 后腹腔注射 CPPD (20 mg/kg) 诱导感染性 AKI。结果：Paricalcitol 预处理则显著提升了 GSH、SOD、GPX4、CAT 和 T-AOC 的水平，增强了肾脏的抗氧化防御。[2] 方法：为研究 Paricalcitol 对内膜增生与狭窄的作用，雌性 Wistar Kyoto 大鼠，股动脉导丝内皮剥脱术(左侧)，右侧假手术对照，术后立即开始腹腔注射给药 Paricalcitol (750 ng/kg) ，隔天一次，持续 2 周。结果：Paricalcitol 组内膜/中膜比(0.17)和狭窄率(28.3%)有下降趋势，但未达统计学显著性。[3] 方法：雄性 Sprague-Dawley 大鼠，行四血管闭塞术(10 分钟)建立全脑缺血模型，缺血后 5 分钟、1 天、2 天、3 天腹腔注射给药 Paricalcitol (1 μg/kg)，观察至缺血后 4 天。结果：Paricalcitol 组 4 天生存率 100% (8/8)，对照组 62.5% (5/8)。[4]
动物实验	After TAC or sham surgery, a subset of the mice is treated with paricalcitol which activates the VDR, at a final dose of 300 ng/kg/day. Paricalcitol is dissolved in a 95% propylene glycol and 5% ethyl alcohol solution. Mice were intraperitoneally injected with paricalcitol (or vehicle only) three times per week on Monday, Wednesday, and Friday for five consecutive weeks. An established anti-hypertrophic and anti-fibrotic treatment, namely the angiotensin II receptor blocker (ARB) losartan is also included. Previous experiments have shown it is feasible and efficacious to dissolve losartan in the drinking water at a concentration of 30 mg/kg/day; mice are treated for five consecutive weeks. So, in total eight groups are studied. Sham (n=10), TAC (n=10), Sham + losartan (Sham-los, n=10), TAC + losartan (TAC-los, n=10), Sham + paricalcitol (Sham-pari, n=10), TAC + paricalcitol (TAC-pari, n=10), Sham + paricalcitol + losartan (Sham-combi, n=10) and TAC + paricalcitol + losartan (TAC-combi, n=10) [2].
别名	帕立骨化醇

化学信息

分子量	416.64
分子式	C₂₇H₄₄O₃
CAS No.	131918-61-1
Smiles	[H][C@@]12CC[C@H]([C@H](C)\C=C\[C@H](C)C(C)(C)O)[C@@]1(C)CCC\C2=C/C=C1C[C@@H](O)C[C@H](O)C1
密度	1.121 g/cm3

储存&溶解度

存储

Powder: -20°C for 3 years Shipping with blue ice/Shipping at ambient temperature.

实际储存温度请以COA为准

溶解度信息

H2O: Insoluble

Ethanol: 12 mg/mL (28.8 mM), Sonication is recommended.

DMSO: 140 mg/mL (336.02 mM), Sonication is recommended.

体内实验配方

10% DMSO+90% Saline: < 10 mg/mL (24 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.

10% DMSO+90% Corn Oil: 3.3 mg/mL (7.92 mM), Sonication is recommended.

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 10 mg/mL (24 mM), Suspension.

请按顺序添加溶剂，在添加下一种溶剂之前，尽可能使溶液澄清。如有必要，可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考，体内配方并不是绝对的，请根据不同情况进行调整。

溶液配制表

Ethanol/DMSO

	1mg	5mg	10mg	50mg
1 mM	2.4002 mL	12.0008 mL	24.0015 mL	120.0077 mL
5 mM	0.4800 mL	2.4002 mL	4.8003 mL	24.0015 mL
10 mM	0.2400 mL	1.2001 mL	2.4002 mL	12.0008 mL
20 mM	0.1200 mL	0.6000 mL	1.2001 mL	6.0004 mL

DMSO

	1mg	5mg	10mg	50mg
50 mM	0.0480 mL	0.2400 mL	0.4800 mL	2.4002 mL
100 mM	0.0240 mL	0.1200 mL	0.2400 mL	1.2001 mL

该溶液配制表仅适用于固体产品。对于液体产品，请根据标明的浓度或密度计算稀释方案。

Paricalcitol

Paricalcitol

产品介绍

引用文献

计算器

体内实验配液计算器

剂量转换

关键词

Paricalcitol

Paricalcitol

Paricalcitol 相关产品

产品介绍

引用文献

计算器

体内实验配液计算器

剂量转换

关键词